Major Durable Response of Pembrolizumab in Chemotherapy Refractory Small Cell Bladder Cancer: A Case Report
Small cell carcinoma of the urinary bladder is a rare subtype (incidence of 1–9/1,000,000), characterized by an aggressive behavior with early metastasis and poor prognosis. Chemotherapy, radiation, and surgery are the usual treatment options, but to date, no accepted standard treatment exists. Sinc...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2020-09-01
|
| Series: | Case Reports in Oncology |
| Subjects: | |
| Online Access: | https://www.karger.com/Article/FullText/509747 |
| _version_ | 1819132152017584128 |
|---|---|
| author | Olav Toai Duc Nguyen Stein Harald Sundstrøm Ganna Surzhykova Westvik Ane Karoline Stræte Røttereng Mona Røli Melhus Cecilie Bergseth Elisabeth Kvelstad Hallem Oluf Dimitri Røe |
| author_facet | Olav Toai Duc Nguyen Stein Harald Sundstrøm Ganna Surzhykova Westvik Ane Karoline Stræte Røttereng Mona Røli Melhus Cecilie Bergseth Elisabeth Kvelstad Hallem Oluf Dimitri Røe |
| author_sort | Olav Toai Duc Nguyen |
| collection | DOAJ |
| description | Small cell carcinoma of the urinary bladder is a rare subtype (incidence of 1–9/1,000,000), characterized by an aggressive behavior with early metastasis and poor prognosis. Chemotherapy, radiation, and surgery are the usual treatment options, but to date, no accepted standard treatment exists. Since small cell bladder cancer shares similar clinicopathological features with small cell lung cancer, the same type of chemotherapy has been used. Recently, immune checkpoint inhibitors have shown effect in small cell lung cancer, but data regarding small cell bladder cancer is insufficient. Here we present a case where a 73-year-old male with chemorefractory metastatic small cell bladder cancer received a successful treatment with immune checkpoint inhibitor pembrolizumab resulting in a major durable response and no side effects. To our knowledge, this is the second case report on successful treatment of the rare subtype of small cell bladder cancer with an immune checkpoint inhibitor, supporting the use of pembrolizumab as a therapeutic option for small cell bladder cancer. Serum neuron-specific enolase was a useful biomarker both for chemo- and immunotherapy response. |
| first_indexed | 2024-12-22T09:26:51Z |
| format | Article |
| id | doaj.art-d8f28835f7f948778045df09535a4c65 |
| institution | Directory Open Access Journal |
| issn | 1662-6575 |
| language | English |
| last_indexed | 2024-12-22T09:26:51Z |
| publishDate | 2020-09-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Case Reports in Oncology |
| spelling | doaj.art-d8f28835f7f948778045df09535a4c652022-12-21T18:31:03ZengKarger PublishersCase Reports in Oncology1662-65752020-09-011331059106610.1159/000509747509747Major Durable Response of Pembrolizumab in Chemotherapy Refractory Small Cell Bladder Cancer: A Case ReportOlav Toai Duc NguyenStein Harald SundstrømGanna Surzhykova WestvikAne Karoline Stræte RøtterengMona Røli MelhusCecilie BergsethElisabeth Kvelstad HallemOluf Dimitri RøeSmall cell carcinoma of the urinary bladder is a rare subtype (incidence of 1–9/1,000,000), characterized by an aggressive behavior with early metastasis and poor prognosis. Chemotherapy, radiation, and surgery are the usual treatment options, but to date, no accepted standard treatment exists. Since small cell bladder cancer shares similar clinicopathological features with small cell lung cancer, the same type of chemotherapy has been used. Recently, immune checkpoint inhibitors have shown effect in small cell lung cancer, but data regarding small cell bladder cancer is insufficient. Here we present a case where a 73-year-old male with chemorefractory metastatic small cell bladder cancer received a successful treatment with immune checkpoint inhibitor pembrolizumab resulting in a major durable response and no side effects. To our knowledge, this is the second case report on successful treatment of the rare subtype of small cell bladder cancer with an immune checkpoint inhibitor, supporting the use of pembrolizumab as a therapeutic option for small cell bladder cancer. Serum neuron-specific enolase was a useful biomarker both for chemo- and immunotherapy response.https://www.karger.com/Article/FullText/509747immunotherapysmall cell bladder carcinomasmall cell carcinomaliver metastasisbiomarkers |
| spellingShingle | Olav Toai Duc Nguyen Stein Harald Sundstrøm Ganna Surzhykova Westvik Ane Karoline Stræte Røttereng Mona Røli Melhus Cecilie Bergseth Elisabeth Kvelstad Hallem Oluf Dimitri Røe Major Durable Response of Pembrolizumab in Chemotherapy Refractory Small Cell Bladder Cancer: A Case Report Case Reports in Oncology immunotherapy small cell bladder carcinoma small cell carcinoma liver metastasis biomarkers |
| title | Major Durable Response of Pembrolizumab in Chemotherapy Refractory Small Cell Bladder Cancer: A Case Report |
| title_full | Major Durable Response of Pembrolizumab in Chemotherapy Refractory Small Cell Bladder Cancer: A Case Report |
| title_fullStr | Major Durable Response of Pembrolizumab in Chemotherapy Refractory Small Cell Bladder Cancer: A Case Report |
| title_full_unstemmed | Major Durable Response of Pembrolizumab in Chemotherapy Refractory Small Cell Bladder Cancer: A Case Report |
| title_short | Major Durable Response of Pembrolizumab in Chemotherapy Refractory Small Cell Bladder Cancer: A Case Report |
| title_sort | major durable response of pembrolizumab in chemotherapy refractory small cell bladder cancer a case report |
| topic | immunotherapy small cell bladder carcinoma small cell carcinoma liver metastasis biomarkers |
| url | https://www.karger.com/Article/FullText/509747 |
| work_keys_str_mv | AT olavtoaiducnguyen majordurableresponseofpembrolizumabinchemotherapyrefractorysmallcellbladdercanceracasereport AT steinharaldsundstrøm majordurableresponseofpembrolizumabinchemotherapyrefractorysmallcellbladdercanceracasereport AT gannasurzhykovawestvik majordurableresponseofpembrolizumabinchemotherapyrefractorysmallcellbladdercanceracasereport AT anekarolinestræterøttereng majordurableresponseofpembrolizumabinchemotherapyrefractorysmallcellbladdercanceracasereport AT monarølimelhus majordurableresponseofpembrolizumabinchemotherapyrefractorysmallcellbladdercanceracasereport AT ceciliebergseth majordurableresponseofpembrolizumabinchemotherapyrefractorysmallcellbladdercanceracasereport AT elisabethkvelstadhallem majordurableresponseofpembrolizumabinchemotherapyrefractorysmallcellbladdercanceracasereport AT olufdimitrirøe majordurableresponseofpembrolizumabinchemotherapyrefractorysmallcellbladdercanceracasereport |